Literature DB >> 36038785

[Prostate and breast cancer: similarities and differences].

Jennifer Kranz1,2, Marco Hoffmann1, Katja Krauß3, Elmar Stickeler3, Matthias Saar4.   

Abstract

Prostate and breast carcinomas are amongst the most common new diseases in men and women, with steadily rising incidences. In addition to the significant health consequences, both diseases also lead to a significantly reduced quality of life due to their influence on sexual function. The aim of this work is to identify scientific approaches and research priorities that in the future might lead to synergies in both disciplines by specifically considering the similarities and differences between the two diseases. For this purpose, clinically relevant aspects such as risk factors, treatment options, as well as scientific similarities and differences that offer direct joint research approaches in the areas of cultivation and modeling of both tumor entities were analyzed. Through this approach, we were able to demonstrate that due to the comparable biology of the two diseases and the underlying mechanisms, scientific synergies may certainly lead to targeted research. Clinical similarities also indicate that close collaboration between the two disciplines could lead to improved treatment of our patients. Evidence deficiencies in both diseases (e.g. the metastasis mechanisms of both tumor entities) and controversially discussed aspects such as risk factors clearly show that further scientific projects for a more detailed understanding of both diseases are necessary to ensure future success in the treatment of our patients.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  BRCA1/2; Hormone therapy; Hypoxia; Neoplasm metastasis; Sexual function

Mesh:

Year:  2022        PMID: 36038785     DOI: 10.1007/s00120-022-01913-5

Source DB:  PubMed          Journal:  Urologie        ISSN: 2731-7064


  32 in total

1.  Body size and composition and prostate cancer risk: systematic review and meta-regression analysis.

Authors:  Robert J MacInnis; Dallas R English
Journal:  Cancer Causes Control       Date:  2006-10       Impact factor: 2.506

Review 2.  Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features.

Authors:  Amanda H Seipel; Brett Delahunt; Hemamali Samaratunga; Lars Egevad
Journal:  Pathology       Date:  2016-06-16       Impact factor: 5.306

3.  Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.

Authors:  Eric A Ariazi; Gary M Clark; Janet E Mertz
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

Review 4.  Unusual subtypes of prostate cancer.

Authors:  David J Grignon
Journal:  Mod Pathol       Date:  2004-03       Impact factor: 7.842

Review 5.  A systematic review and meta-analysis of familial prostate cancer risk.

Authors:  L E Johns; R S Houlston
Journal:  BJU Int       Date:  2003-06       Impact factor: 5.588

6.  The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004.

Authors:  Christie R Eheman; Kate M Shaw; Aliza Blythe Ryerson; Jacqueline W Miller; Umed A Ajani; Mary C White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

7.  Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor.

Authors:  Takashi Suzuki; Yasuhiro Miki; Takuya Moriya; Norihiro Shimada; Takanori Ishida; Hisashi Hirakawa; Noriaki Ohuchi; Hironobu Sasano
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

8.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

9.  Diabetes mellitus and risk of prostate cancer: a meta-analysis.

Authors:  S Bonovas; K Filioussi; A Tsantes
Journal:  Diabetologia       Date:  2004-05-26       Impact factor: 10.122

10.  Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Authors:  Alex Tsodikov; Roman Gulati; Eveline A M Heijnsdijk; Paul F Pinsky; Sue M Moss; Sheng Qiu; Tiago M de Carvalho; Jonas Hugosson; Christine D Berg; Anssi Auvinen; Gerald L Andriole; Monique J Roobol; E David Crawford; Vera Nelen; Maciej Kwiatkowski; Marco Zappa; Marcos Luján; Arnauld Villers; Eric J Feuer; Harry J de Koning; Angela B Mariotto; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2017-09-05       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.